Company Update (NASDAQ:GILD): European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

[Business Wire] – Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Zydelig® , 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers – chronic . . . → Read More: Company Update (NASDAQ:GILD): European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma Similar Articles: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma Gilead Sciences Inc (NASDAQ:GILD) | Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences Announces First Quarter 2014 Financial Results